PURPOSE: To correlate the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) with ocular symptoms typical of rheumatoid arthritis (RA). METHODS: The records of 451 patients who had been examined by an ophthalmologist and tested for anti-CCP antibodies over a 3-year period at the Mayo Clinic were reviewed. Records of 255 patients with titers of anti-CCP and RF were analyzed for ocular surface and inflammatory disease associated with ocular RA. RESULTS: Of the 33 anti-CCP+/RF+ patients, all were diagnosed with RA; ocular surface disease was present in 11 (33%) and inflammatory disease in 7 (21%). Of the 17 anti-CCP-/RF+ patients, 4 were diagnosed with an unspecified inflammatory arthritis and 1 with rheumatoid arthritis; a separate 5 (29%) had ocular surface disease. Out of 5 anti-CCP+/RF- patients, 3 were diagnosed with RA but none had ocular symptoms. Out of 200 anti-CCP-/RF- patients, 32 (16%) had ocular surface disease and 2 (1%) had ocular inflammation. Of the 74 patients diagnosed with any form of inflammatory arthritis, anti-CCP+/RF+ patients had more and worse inflammatory ocular RA disease compared to the other groups. CONCLUSIONS: Patients who were both anti-CCP and RF positive tended to have more and worse ocular disease. In patients diagnosed with an inflammatory arthritis, the presence of anti-CCP antibodies and RF provides useful information to ophthalmologists for identifying patients most at risk for inflammatory ocular disease.
PURPOSE: To correlate the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) with ocular symptoms typical of rheumatoid arthritis (RA). METHODS: The records of 451 patients who had been examined by an ophthalmologist and tested for anti-CCP antibodies over a 3-year period at the Mayo Clinic were reviewed. Records of 255 patients with titers of anti-CCP and RF were analyzed for ocular surface and inflammatory disease associated with ocular RA. RESULTS: Of the 33 anti-CCP+/RF+ patients, all were diagnosed with RA; ocular surface disease was present in 11 (33%) and inflammatory disease in 7 (21%). Of the 17 anti-CCP-/RF+ patients, 4 were diagnosed with an unspecifiedinflammatory arthritis and 1 with rheumatoid arthritis; a separate 5 (29%) had ocular surface disease. Out of 5 anti-CCP+/RF- patients, 3 were diagnosed with RA but none had ocular symptoms. Out of 200 anti-CCP-/RF- patients, 32 (16%) had ocular surface disease and 2 (1%) had ocular inflammation. Of the 74 patients diagnosed with any form of inflammatory arthritis, anti-CCP+/RF+ patients had more and worse inflammatory ocular RA disease compared to the other groups. CONCLUSIONS:Patients who were both anti-CCP and RF positive tended to have more and worse ocular disease. In patients diagnosed with an inflammatory arthritis, the presence of anti-CCP antibodies and RF provides useful information to ophthalmologists for identifying patients most at risk for inflammatory ocular disease.
Authors: D D McGavin; J Williamson; J V Forrester; W S Foulds; W W Buchanan; W C Dick; P Lee; R N MacSween; K Whaley Journal: Br J Ophthalmol Date: 1976-03 Impact factor: 4.638
Authors: Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns Journal: J Immunol Date: 2003-07-15 Impact factor: 5.422
Authors: Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij Journal: Arthritis Rheum Date: 2003-10
Authors: Louise M A Jansen; Dirkjan van Schaardenburg; Irene van der Horst-Bruinsma; Rob J van der Stadt; Margret H M T de Koning; Ben A C Dijkmans Journal: J Rheumatol Date: 2003-08 Impact factor: 4.666
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-02
Authors: S W Syversen; P I Gaarder; G L Goll; S Ødegård; E A Haavardsholm; P Mowinckel; D van der Heijde; R Landewé; T K Kvien Journal: Ann Rheum Dis Date: 2007-05-25 Impact factor: 19.103
Authors: Sheila T Angeles-Han; Christina F Pelajo; Larry B Vogler; Kelly Rouster-Stevens; Christine Kennedy; Lori Ponder; Courtney McCracken; Jorge Lopez-Benitez; Carolyn Drews-Botsch; Sampath Prahalad Journal: J Rheumatol Date: 2013-11-01 Impact factor: 4.666